Keywords: s-p, boceprevir, reduces, svr, after, weeks, ph
S-P's boceprevir reduces SVR after 28 weeks in Ph II study
Article | 24 April 2009
US drug major Schering-Plough's boceprevir, its investigational oral hepatitis C protease inhibitor, significantly increased sustained virologic response rates with 28 and 48 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
